Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.
BACKGROUND
In Japan, generally, patients with chronic hepatitis C are aged. The aim of this study was to investigate the effect of interferon (IFN) therapy on the mortality of chronic hepatitis C patients over age 60.


METHODS
Seven-hundred and seven patients with histologically proven chronic hepatitis C were enrolled in this study; 649 received IFN therapy (IFN group) and 58 did not (control group). The standardized mortality ratio (SMR) and Cox proportional hazard regression analysis were used to evaluate the effect of IFN on the survival of the patients.


RESULTS
Mean follow-up periods in the IFN and control groups were 5.7 and 6.7 years, respectively. During follow-up, 13 patients in the control group died (7 of liver-related diseases) and 42 in the IFN group died (29 of liver-related diseases). The SMRs of the control and IFN groups were 1.40 (95% confidence interval [CI], 0.76-2.45) and 0.73 (95% CI, 0.52-0.98) for overall death, and 10.70 (95% CI, 4.29-22.05) and 5.05 (95% CI, 3.38-7.26) for liver-related death, respectively. Sustained and transient biochemical responders in the IFN group (SMR, 0.53; 95% CI, 0.01-2.97 and SMR, 3.25; 95% CI, 0.87-8.32, respectively) showed lower liver-related mortality compared with the control group. In patients with sustained virological response, liver-related mortality was also very low (SMR, 0.65; 95% CI, 0.01-3.61). The risk for liver-related death of sustained and transient biochemical responders was also low compared with that of the control group (adjusted risk ratios 0.10 [95% CI, 0.01-0.95] and 0.50 [95% CI, 0.11-2.21], respectively).


CONCLUSIONS
These results suggest that IFN treatment could reduce liver-related mortality in chronic hepatitis C patients over age 60, notably in patients showing a biochemical response and in those showing a sustained virological response.
Imai
Yasuharu
Y
Department of Internal Medicine, Ikeda Municipal Hospital, 3-1-18 Johnan, 563-8510, Ikeda, Japan.
Kasahara
Akinori
A
Tanaka
Hideo
H
Okanoue
Takeshi
T
Hiramatsu
Naoki
N
Tsubouchi
Hirohito
H
Yoshioka
Kentaro
K
Kawata
Sumio
S
Tanaka
Eiji
E
Hino
Keisuke
K
Hayashi
Katsuhiro
K
Tamura
Shinji
S
Itoh
Yoshito
Y
Sasaki
Yutaka
Y
Kiyosawa
Kendo
K
Kakumu
Shinichi
S
Okita
Kiwamu
K
Hayashi
Norio
N
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D000998:Antiviral Agents; D007372:Interferons; D000410:Alanine Transaminase